Furthermore, IATL enhances the sensitivity of prostate cancer to cisplatin-based treatments by cooperating with cisplatin to increase ER stress and activate the JNK signaling pathway [16, 28–30, 41]. Here, MAPK8 is linked to prostate carcinoma.